Active substanceAminophenylbutyric acidAminophenylbutyric acid
Similar drugsTo uncover
  • Anvifen®
    capsules inwards 
    Anvilab, OOO     Russia
  • Noofen®
    capsules inwards 
    Olainfarm, AO     Latvia
  • Fenibut
    pills inwards 
  • Fenibut
    pills inwards 
    ORGANICS, JSC     Russia
  • Fenibut
    pills inwards 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Fenibut
    pills inwards 
  • Fenibut
    pills inwards 
  • Fenibut
    pills inwards 
    TRIM, LLC     Russia
  • Fenibut-LekT
    pills inwards 
    PATENT-FARM, CJSC     Russia
  • Dosage form: & nbsppills
    Composition:

    Composition per one tablet.

    Active substance: aminophenylbutyric acid hydrochloride (phenybut) 250 mg

    Excipients: lactose monohydrate - 180 mg, potato starch - 56 mg, povidone (polyvinylpyrrolidone low molecular weight medical) - 9 mg, calcium stearate monohydrate - 5 mg.

    Description:

    Tablets are white or white with a slightly yellowish hue of a flat-cylindrical shape with a facet and a risk.

    Pharmacotherapeutic group:nootropic remedy
    ATX: & nbsp

    N.06.B   Psychostimulants and nootropic drugs

    Pharmacodynamics:

    Nootropic agent, facilitates GABA (y-aminobutyric acid) - mediated transmission of nerve impulses in the central nervous system (direct effect on GABA-ergic receptors).The tranquilizing effect is combined with the activating effect. It also has antiplatelet, antioxidant and some anticonvulsant action.

    It improves the functional state of the brain due to the normalization of its metabolism and influence on the cerebral blood flow (increases volumetric and linear speed, reduces vascular resistance, improves microcirculation).

    Does not affect cholino- and adrenergic receptors. It prolongs the latent period and shortens the duration and severity of nystagmus. Reduces vasovegetative symptoms (including headache, sensation of heaviness in the head, sleep disorders, irritability, emotional lability). At the course reception increases physical and mental efficiency (attention, memory, speed and accuracy of sensory-motor reactions). Reduces the manifestation of asthenia (improves well-being, increases interest and initiative (motivation of activity)) without sedation or arousal.

    Helps reduce feelings of anxiety, tension and anxiety, normalizes sleep.

    People of advanced age do not cause central nervous system depression, muscle-relaxing aftereffect is most often absent.

    Reduces the inhibitory effect of ethanol on the central nervous system.
    Pharmacokinetics:

    Absorption is high, the drug penetrates well into all tissues of the body and across the blood-brain barrier (in the brain tissue penetrates about 0.1% of the administered dose of the drug, and in young and old people to a much greater extent). Evenly distributed in the liver and kidneys. Metabolized in the liver - 80-95%, metabolites are pharmacologically inactive. Do not cumulate. After 3 hours begins to be excreted by the kidneys, while the concentration in the brain tissue does not decrease, and it is found in the brain for another 6 hours. About 5% is excreted by the kidneys unchanged, partially removed from the bile.

    Indications:

    - asthenic and anxiety-neurotic states

    - stuttering, tics and enuresis in children

    - Insomnia and nighttime anxiety in the elderly

    - Meniere's disease, dizziness associated with dysfunction of the vestibular analyzer of various genesis; prevention of motion sickness with kinetosis

    - as part of complex therapy in the treatment of alcohol withdrawal syndrome.

    Contraindications:

    Hypersensitivity, children under 8 years.Patients with rare hereditary diseases, such as lactose intolerance, lactase deficiency or glucose-galactose malabsorption should not take the drug (due to the presence of lactose).

    Carefully:

    Carefully with erosive and ulcerative lesions of the gastrointestinal tract, hepatic insufficiency, pregnancy, during lactation.

    Dosing and Administration:

    Inside after eating 2-3 week courses.

    Adults and children from 14 years of age are prescribed 250-500 mg 3 times a day (maximum daily dose of 1500 mg). Children from 8 to 14 years - 250 mg 3 times a day. A single maximum dose in adults and children from the age of 14 is 750 mg, in people over 60 years - 500 mg, from 8 to 14 years, 250 mg.

    Cessation of alcohol withdrawal syndrome in the first days of treatment: during the day, 250-500 mg 3 times a day and 750 mg at night, with a gradual decrease in the daily dose to normal for adults.

    Prevention of motion sickness: 250-500 mg once for 1 hour before the expected start of the pitching or with the appearance of the first mild symptoms of seasickness. The anti-sweating effect of Phenibutum increases with an increase in the dose of the drug. At the onset of severe manifestations of seasickness (vomiting, etc.), the administration of phenibutum is ineffective even in doses of 750-1000 mg.

    Otogenic labyrinthite and Meniere's disease during an exacerbation: 750 mg 3-4 times a day for 5-7 days, with a decrease in the severity of vestibular disorders - 250-500 mg 3 times a day for 5-7 days and then 250 mg once a day for 5 days. For mild disease, 250 mg twice a day for 5-7 days, followed by a dose reduction of 250 mg once a day for 7-10 days.

    Asthenic conditions: by mouth, 40-80 mg / day, in some cases - up to 200-300 mg / day for 1-1.5 months.

    Depressive states of late age - 2-3 times a day for 40-200 mg / day for 1.5-3 months.

    Side effects:

    Increased irritability, agitation, anxiety, dizziness, headache, drowsiness, nausea (with the first techniques), allergic reactions (skin rash, itching).

    Overdose:

    Symptoms: severe drowsiness, nausea, vomiting, fatty degeneration of the liver (reception more than 7000 mg), eosinophilia, lowering blood pressure, impaired renal function.

    Treatment: gastric lavage, reception of activated charcoal and symptomatic therapy.

    Interaction:

    Extends and intensifies the effect of sleeping pills, narcotic analgesics, neuroleptics, antiparkinsonian and antiepileptic drugs.

    Special instructions:With prolonged use, it is necessary to monitor the performance of the liver and peripheral blood.
    Effect on the ability to drive transp. cf. and fur:

    It is necessary to refrain from potentially dangerous activities requiring increased attention.

    Form release / dosage:

    Tablets of 250 mg.

    Packaging:10 tablets per contour cell pack. By 2, 3 or 5 contour mesh packages with instructions for use are placed in a pack of cardboard.
    Storage conditions:

    In the dark place at temperature not higher than 25 ° ะก.

    Keep out of the reach of children.
    Shelf life:

    3 years. Do not use after expiration date, indicated on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:P N002841 / 01
    Date of registration:24.06.2008
    The owner of the registration certificate:MOSCOW ENDOCRINE FACTORY, FSUE MOSCOW ENDOCRINE FACTORY, FSUE Russia
    Manufacturer: & nbsp
    Information update date: & nbsp09.09.2014
    Illustrated instructions
      Instructions
      Up